Quest Diagnostics (DGX) Stock Price
Quest Diagnostics Price
Over the last 19 years Quest Diagnostics grew revenue by 3.0% annually, reaching 11.04 B USD. Earnings per share have grown at 5.8% per year over the last 19 years. For Quest Diagnostics, the net margin of 9.0% is down versus 18.5% a few years ago. At today's price the dividend yield works out to roughly 1.37%. The payout ratio is around 36% of earnings. The dividend has grown at 11.6% per year over the past 19 years. The consensus 12-month price target for Quest Diagnostics is 247.50 USD, about 7.3% above where the stock trades today. Of 23 analysts, 13 rate the stock a buy — an overall Buy consensus.
Quest Diagnostics stock price
Quest Diagnostics business model & stock analysis
Frequently asked questions about Quest Diagnostics
Quest Diagnostics Inc. operates as a provider of diagnostic testing and information services. It offers a range of services including routine testing, complex and specialized testing, and diagnostic information services. The company operates a network of laboratories, patient service centers, and other testing sites across the United States. Quest Diagnostics Inc. collaborates with physicians, hospitals, and other healthcare organizations to help improve patient care. Its business model revolves around delivering accurate and reliable diagnostic testing results in a timely manner, assisting healthcare providers in making informed decisions, and ultimately improving patient outcomes.
Quest Diagnostics Inc is primarily active in the healthcare industry.
The main competitors of Quest Diagnostics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Sonic Healthcare Limited, and Bio-Reference Laboratories.
Quest Diagnostics Inc is a leading provider of diagnostic information services. It was founded in 1967 as MetPath and became Quest Diagnostics in 1997. The company offers a wide range of services, including lab testing, clinical trials, and healthcare IT solutions. With a strong focus on innovation and quality, Quest Diagnostics has become a trusted name in the healthcare industry. It operates a vast network of laboratories across the United States, serving millions of patients and healthcare professionals. Quest Diagnostics is known for its commitment to accuracy, efficiency, and delivering timely results, making it a reliable partner for both patients and healthcare providers.
Quest Diagnostics Inc has achieved several significant milestones throughout its history. One of its noteworthy achievements includes the development of innovative diagnostic tests and services that have revolutionized the healthcare industry. Additionally, Quest Diagnostics Inc has successfully established a vast network of laboratories and patient service centers, ensuring convenient access to high-quality diagnostic information services for patients worldwide. Furthermore, the company has received numerous accolades for its commitment to quality, including ISO 9001 certification for its laboratory operations. These accomplishments highlight Quest Diagnostics Inc as a leading provider of diagnostic information services and showcase its dedication to improving patient care and outcomes.
Quest Diagnostics Inc is primarily present in the United States.
Quest Diagnostics Inc represents values of empowerment, collaboration, and integrity. As a leading provider of diagnostic testing and information services, the company is committed to delivering high-quality healthcare solutions. Quest Diagnostics believes in patient-centric care and strives to improve both individual and public health outcomes. With a corporate philosophy focused on innovation and excellence, Quest Diagnostics prioritizes accuracy, efficiency, and accessibility in their diagnostic services. Through extensive research and development, the company continually advances medical technologies to contribute to the progress of the healthcare industry.
Analysts currently set an average price target of 244.50 USD for the Quest Diagnostics stock (median: 247.50 USD), implying +6.0 % versus the latest price. The consensus is based on 23 analyst ratings.
23 analysts currently rate the Quest Diagnostics stock: 13 recommend buying, 10 holding and 0 selling. For 2026, analysts expect Quest Diagnostics to generate revenue of 12.01 B USD and earnings per share of 11.29 USD.
Converted at the current exchange rate, the Quest Diagnostics share trades at 205.84 EUR (230.60 USD).
The Quest Diagnostics share (DGX) is listed on 8 stock exchanges, including: NYSE (DGX), London (0KSX.L), SIX (Zürich) (QDI.SW), XETRA (QDI.DE), Frankfurt (QDI.F), München (QDI.MU), Düsseldorf (QDI.DU).
Quest Diagnostics Inc is a leading provider of diagnostic laboratory tests and services worldwide. The company serves medical laboratories, hospitals, clinics, physicians, as well as companies and insurers globally. The company's business strategy is based on providing high-quality laboratory facilities, state-of-the-art technology, and a high-quality laboratory workflow management platform. It operates over 2,200 patient centers in the United States and also offers a mobile laboratory service. The company is divided into three main segments: 1. Diagnostic information services, 2. Diagnostic services, and 3. Diagnostic solutions. Quest Diagnostics offers a wide range of products and services used to diagnose and treat diseases and conditions, including blood tests, hormone analyses, microbiology tests, genetic tests, immunology tests, and more. The company also operates a pathology laboratory that provides specialized services for cancer diagnosis and other critical diseases. It has also specialized in the development of tests for detecting COVID-19. Overall, Quest Diagnostics has a strong business model based on its leading position in the diagnostic market, a wide range of products and services, and a strong presence in the United States and growing international presence. The company is also focused on expanding its capabilities in digital health technology to meet the changing healthcare landscape.
The expected revenue of Quest Diagnostics is 12.01 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Quest Diagnostics is 1.26 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Quest Diagnostics is currently 20.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Quest Diagnostics stock.
The price-to-sales ratio (P/S) of Quest Diagnostics is currently 2.15. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Quest Diagnostics stock.
The Eulerpool Quality Score for Quest Diagnostics is 2/10.
The ISIN of Quest Diagnostics is US74834L1008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Quest Diagnostics is 904533. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Quest Diagnostics is DGX. The ticker symbol is used to trade Quest Diagnostics shares on the stock exchange.
Quest Diagnostics stock
Quest Diagnostics Peer Group
Quest Diagnostics Ticker
Quest Diagnostics FIGI
All fundamentals and in-depth analysis of Quest Diagnostics
Our stock analysis for Quest Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quest Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.